We claim:
1. A compound of formula (I),
or their stereoisomers and pharmaceutically acceptable salts thereof,
5 wherein,
X is independently selected from O or S;
Y is independently selected from CH2 or NH;
R1
is hydrogen or –(C1-6)-alkyl;
R2
is hydrogen or –(C1-6)-alkyl;
R3 10 is –(C6-10)-aryl, -(C3-6)-cycloalkyl or –(C5-10)-heteroaryl; each of which is
optionally substituted with one or more substituents selected from halogen, -(C1-
6)-alkyl;
ring A is selected from the group consisting of:
15 “ ” represents point of attachment;
R4
is –(C5-10)-heteroaryl, O-(CH2)n-NH2; n is 0, 1 or 2;
2. The compound as claimed in claim 1, wherein the compound is selected from
the group consisting of:
2-(4-(4-methyl piperazin-1-yl) phenyl amino)-N-(2-(4-fluorophenyl) propan-2-
20 yl)-5,6-dihydropyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
2-(4-(4-methylpiperazin-1-yl) phenyl amino)-N-(cyclopropylmethyl)-5,6-
dihydro pyrido [3,4-d] pyrimidine-7(8H)-carboxamide;
2-(4-(4-methylpiperazin-1-yl) phenylamino)-5,6-dihydro-N-((1-
methylpiperidin-4-yl) methyl) pyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
25 2-(4-(4-methylpiperazin-1-yl) phenyl amino)-5,6-dihydro-N-((tetrahydro-2Hpyran-4-yl) methyl) pyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
37
2-(4-(2-aminoethoxy) phenylamino)-N-(4-fluorobenzyl)-5,6-
dihydropyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
2-(1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-ylamino)-N-(4-fluorobenzyl)-
5,6-dihydropyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
5 2-(4-(4-methylpiperazin-1-yl) phenyl amino)-N-(4-fluorobenzyl)-5,6-dihydro
pyrido[3,4-d] pyrimidine-7(8H)-carbothioamide;
2-(4-(4-methylpiperazin-1-yl) phenylamino)-N-(1-(4-fluorophenyl) ethyl)-5,6-
dihydropyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
N-(2,4-difluorobenzyl)-2-(4-(4-methylpiperazin-1-yl) phenyl amino)-5,6-
10 dihydro pyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
2-(4-((4-methylpiperazin-1-yl) methyl) phenylamino)-N-(4-fluorobenzyl)-5,6-
di hydro pyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
2-(4-(morpholino methyl) phenyl amino)-N-(4-fluorobenzyl)-5,6-dihydro
pyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
15 N-(3-fluorobenzyl)-2-(4-(4-methylpiperazin-1-yl) phenylamino)-5,6-dihydro
pyrido[3,4-d] pyrimidine-7(8H)-carboxamide;
N-(2-fluorobenzyl)-2-(4-(4-methylpiperazin-1-yl) phenylamino)-5,6-dihydro
pyrido[3,4-d] pyrimidine-7(8H)-carboxamide; and
1-(2-(4-(4-methylpiperazin-1-yl) phenylamino)-5,6-dihydropyrido[3,4-d]
20 pyrimidin-7(8H)-yl)-3-(4-fluorophenyl) propan-1-one.
3. A pharmaceutical composition comprising the compound of formula (I), or a
stereoisomer, or a pharmaceutically acceptable salt thereof as claimed in claim
1 or claim 2 and pharmaceutically acceptable excipients.
4. The pharmaceutical composition as claimed in claim 3, for use in the treatment
25 of disease or disorders that are associated with abnormal cellular proliferation
such as cancers.
5. A method of treating disease or disorder that are associated with abnormal
cellular proliferation such as cancers comprising administering to a patient in
need thereof, a therapeutically effective amount of the compound of formula (I),
30 or, a stereoisomer, or a pharmaceutically acceptable salt thereof as claimed in
any one of claims 1 to 2.
38
6. Use of the compound of formula (I), or a stereoisomer, or a pharmaceutically
acceptable salt thereof as claimed in any one of claims 1 to 2 for the manufacture
of a medicament for the treatment of disease or disorder that are associated with
abnormal cellular proliferation such as cancers.